In 2024, spevigo was approved for the treatment of gpp in adults and pediatric patients aged 12 and above weighing ≥40 kg The mechanism of spesolimab effects in generalized pustular psoriasis (gpp) has not been determined In adults experiencing gpp flares, spevigo is administered once by intravenous (iv.
Spevigo (spesolimab) is used to treat generalized pustular psoriasis (gpp) in adults and children 12 years and older who weigh at least 88 pounds (40 kg) Fda expands approval of spevigo ® for generalized pustular psoriasis spevigo ® is now approved to treat gpp in adults and children aged 12 and above. This monoclonal antibody therapy is given by intravenous infusion when used to treat a gpp flare, and by subcutaneous (under the skin) injection every 4 weeks when used for maintenance gpp treatment
It is not known if spevigo is safe and effective in children under 12 years of age or who weigh less than 88 pounds (40 kg). This medication is a biologic that's called an interleukin antagonist For gpp flares, spevigo (spesolimab) is given as an infusion through the vein (iv) by a healthcare professional Side effects include fatigue and nausea for the iv infusion
For continued treatment of gpp.
